Sun Pharmaceutical Industries Ltd. closed 8.26% below its 52-week high of 1,885.00 rupees, which the company reached on ...

Sun Pharmaceutical Industries Ltd. closed 4.84% short of its 52-week high of 1,850.95 rupees, which the company achieved on May 2nd.

Natco’s escalates the legal battle over semaglutide, one of the world’s most valuable and closely contested pharmaceutical ...

A revolution in India’s weight-loss market is coming. As Semaglutide’s patent ends in 2026, Sun Pharma, Lupin, Torrent, and ...

They have also shared an outlook on pharma, telecom, internet platforms, banking, metals and consumer sectors, alongside ...

Sun Pharmaceutical Industries targets mid- to high-single digit topline growth in FY26, focusing on innovative medicines and ...

Indian drugmakers primarily produce generics, or copycat versions, and in order to enter the market, they either have to wait ...

Obesity treatment drugs to drive pharma industry growth in India. Sun Pharma highlights GLP-1 impact. Innovation & ...

Sun Pharma’s focus areas involve investing in research and development (R&D) to further build its pipeline of innovative medicines.

Vishal Manchanda, Pharma Analyst at Systematix Group, said that when it comes to investing in the GLP-1 theme, the Indian ...

The US-Venezuela tensions has turned the spotlight on shares of companies like Indian Oil Corp, Oil India, Sun Pharma, Dr ...

Halvio Capital returned 5.62 percent this quarter while exploring international value opportunities. View our latest partner ...